NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Proposed Single Technology Appraisal

Erenumab for preventing migraine ID1188

Provisional matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
Company Norvartis (erenumab) Patient/carer groups Action on Pain Brain and Spine Foundation Disability Rights UK Leonard Cheshire Disability Migraine Action Migraine Trust Muslim Council of Britain National Migraine Centre Neurological Alliance OUCH UK Pain Concern Pain Relief Foundation Pain UK South Asian Health Foundation Pain UK South Asian Health Foundation Pain UK South Asian Health Foundation British Association of British Neurologists British Association for the Study of Headache British Geriatrics Society British Pain Society Institute of Neurology National Pharmacy Association Primary Care Neurology Society Royal College of Anaesthetists Royal College of General Practitioners Royal College of Nursing	General Allied Health Professionals Federation Board of Community Health Councils in Wales British National Formulary Care Quality Commission Department of Health, Social Services and Public Safety for Northern Ireland Healthcare Improvement Scotland Medicines and Healthcare products Regulatory Agency National Association of Primary Care National Pharmacy Association Neurological Alliance of Scotland NHS Alliance NHS Commercial Medicines Unit NHS Confederation Scottish Medicines Consortium Wales Neurological Alliance Welsh Health Specialised Services Committee Possible comparator manufacturers None Relevant research groups British Neurological Research Trust Cochrane Pain, Palliative Care and Supportive Care Group MRC Clinical Trials Unit National Institute for Health Research Associated Public Health Groups Public Health England Public Health Wales
 Royal College of Pathologists 	

National Institute for Health and Clinical Excellence

Provisional matrix for the proposed technology appraisal of erenumab for preventing migraine ID1188

Issue date: May 2017

Appendix C

Consultees	Commentators (no right to submit or appeal)
 Royal College of Physicians Royal Pharmaceutical Society Royal Society of Medicine UK Clinical Pharmacy Association 	
Others Department of Health NHS East Surrey CCG NHS England NHS Vale Royal CCG Welsh Assembly Government	

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Issue date: May 2017

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Appraisal Determination (FAD).

All non company consultees are invited to submit a statement¹, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland;; related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the British National Formulary.

All non company commentators are invited to nominate clinical or patient experts.

National Institute for Health and Clinical Excellence Provisional matrix for the proposed technology appraisal of erenumab for preventing migraine ID1188

Issue date: May 2017

¹ Non company consultees are invited to submit statements relevant to the group they are representing.